Sosei Heptares to Regain Worldwide Rights to Muscarinic Agonist Programs
TOKYO and CAMBRIDGE, England, Jan. 5, 2021 /PRNewswire/ — Sosei Group Corporation (“the Company”) (TSE: 4565) announces it is to regain the worldwide rights to its muscarinic agonist programs. The program was licensed to Allergan in April 2016, and Allergan was acquired by AbbVie in May…
Comments Off on Sosei Heptares to Regain Worldwide Rights to Muscarinic Agonist Programs